DNSP-11
GDNF propeptide with striking dopamine data — from injection into the brain.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About DNSP-11
DNSP-11 is an 11-amino-acid peptide from the pro-region of glial cell line-derived neurotrophic factor, predicted to be cleaved from the proprotein at flanking dibasic sites. Its animal data is genuinely notable: a single injection into the substantia nigra of a normal adult rat was taken up rapidly into neurons and raised resting dopamine and its metabolites for up to 28 days, and in a 6-hydroxydopamine rat model of Parkinson's it improved apomorphine-induced rotational behaviour and increased nigral dopamine levels. In vitro it supports survival and neurite outgrowth of fetal mesencephalic neurons. The route is the whole story, though. That single injection went directly into the substantia nigra — stereotactic intracranial delivery. Nothing about that result implies a subcutaneous injection of an 11-mer would reach dopaminergic midbrain neurons. There are no human trials.
Key Benefits
- Raised rat nigral dopamine for up to 28 days from a single dose
- Improved motor behaviour in a 6-OHDA Parkinson's rat model
- Supports dopaminergic neuron survival and neurite outgrowth in vitro
- Derived from a conserved region of the GDNF proprotein
Set a goal (top of the page) to see how DNSP-11 scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Unknown — no human safety data exists
- Injection site reactions
- Systemic dopaminergic effects uncharacterised
Legal & Regulatory Status
Research use only. Not FDA-approved and never tested in humans. All efficacy data comes from direct intracranial administration in rats.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- Dopamine neuron stimulating actions of a GDNF propeptide — original in vivo characterisation (PMC2841203)
- Dynamic changes in dopamine neuron function after DNSP-11 treatment (PMID 24406899)
- Physical and in vitro protective activity of three peptides from the pro- and mature GDNF sequence (PMC3091812)
- Small molecules and peptides targeting GDNF receptors for neurodegeneration — review (PMC7554781)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 5mg $122.3210mg $216.26
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.